Entecavir is a potent anti-HBV drug superior to lamivudine: Experience from clinical trials in China

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 2, 2007, Pages 201-205

  Yao, Guangbi ^a  

^a Shanghai Jing An Qu Central Hospital   (China)

Author keywords

Antiviral therapy; Efficacy; Hepatitis B virus; Resistance; Safety

Indexed keywords

ENTECAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PLACEBO;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CHINA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EXPERIENCE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER INJURY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PATIENT MONITORING; SCREENING; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHINA; DRUG RESISTANCE, VIRAL; GUANINE; HEPATITIS B; HUMANS; LAMIVUDINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34547841575     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm175     Document Type: Editorial

References (23)

1. Hepatitis B fact sheet WHO/204 Geneva: World Health Organization. October 2000. http:/Www.who.int/infs/en/fact204.html (21 December 2005, date last accessed).
2. Liang XF, Chen YS, Wang XJ et al. A study on the sero-epidemiology of hepatitis B in Chinese population aged over 3-years old. Chin J Epidemiol 2005; 26: 655-60.
3. Lok ASF, McMahon BJ. AASLD practice guidelines: Chronic hepatitis B. Hepatology 2007; 45: 507-39.
4. Innaimo SF, Seifer M, Bisacchi GS et al. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997; 41: 1444-8.
5. Levine S, Hernandez D, Yamanaka G et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 2525-32.
6. Tenney DJ, Levine SM, Rose RE et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-507.
7. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006; 44: 1656-65.
8. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-11.
9. Yen JH, Bifano M, Nichola P et al. Entecavir pharmacokinetics after multiple doses in healthy subjects. J Clin Pharmacol 2002; 42 Suppl 1: 1070 (and poster presented at the Thirty-first American College of Clinical Pharmacy Annual Meeting, San Francisco, CA, USA, 2002).
10. Yan JH, Bifano M, Olsen S et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharm 2006; 46: 1250-8.
11. Yao G-B, Xu D-Z, Wang B-E et al. A phase II study in China of the safety and antiviral activity of entecavir in adults with chronic hepatitis B infection. Hapatology 2003; 38 Suppl 1: 711A (and poster presented at the Fifty-fourth Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA, 2003).
12. Yao G, Chen CW, Lu WL et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B: Results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients. J Hapatol 2006; 44 Suppl 2: S193 (abstract 519) (and poster presented at the Forty-first Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 2006).
13. Yao G, Chen CW, Lu WL et al. Entecavir achieves superior virologic response compared to lamivudine for the treatment of chronic hepatitis B: 2-year results from a phase 3 study in nucleoside-naive Chinese patients in China (ETV-023). Hepatology 2006; 44 Suppl 1: 559-60A (abstract 997) (and poster presented at the Fifty-seventh Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA, 2006).
14. Yao G, Zhou X, Xu D et al. Entecavir results in early viral load reduction in chronic hepatitis B patients who have failed lamivudine therapy: A randomized, placebo-controlled study in China (Study ETV-056). J Hapatol 2006; 44 Suppl 2: S193 (abstract 518) (and poster presented at the Forty-first Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, 2006).
15. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
16. Lal CL, Shouval D, Lok ASP et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1010-20.
17. Sherman M, Yurdaydin C, Sollano J et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
18. Fung SK, Lok ASF. Hepatigs B virus genotypes: Do they play a role in the outcome of HBV infection? Hepatology 2004, 40: 790-2.
19. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
20. Zoulim F. Hepatitis-B virus resistance to entecavir in nucleoside naive patients: Does it exist? Hepatology 2006; 44: 1404-7.
21. Chinese Society of Hepatology and Chinese Society of Infectious Disease. Chinese guideline for the prevention and management of chronic hepatitis B. Chin Hepatol 2005; 10: 348-57.
22. Yao G, Zhang D, Wang B et al. A study of the dosage and efficacy of entecavir for treating hepatitis B virus. Chin J Hepatol 2005, 13: 484-7.
23. Yao G, Ji Y, Ran H et al. One year trial of entecavir for Chinese chronic hepatitis B patients failed with lamivudine therapy. Chin J Infect Dis 2006; 24: 385-9.